Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)193.36
  • Today's Change0.42 / 0.22%
  • Shares traded1.28m
  • 1 Year change+25.98%
  • Beta0.6213
Data delayed at least 15 minutes, as of Sep 19 2024 17:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform17
Hold8
Sell0
Strong Sell0

Share price forecast in USD

The 25 analysts offering 12 month price targets for AbbVie Inc have a median target of 200.00, with a high estimate of 218.00 and a low estimate of 170.00. The median estimate represents a 3.66% increase from the last price of 192.94.
High13.0%218.00
Med3.7%200.00
Low-11.9%170.00

Dividends in USD

In 2023, AbbVie Inc reported a dividend of 5.92 USD, which represents a 4.96% increase over last year. The 13 analysts covering the company expect dividends of 6.23 USD for the upcoming fiscal year, an increase of 5.27%.
Div growth (TTM)4.96%
More ▼

Earnings history & estimates in USD

On Jul 25, 2024, AbbVie Inc reported 2nd quarter 2024 earnings of 2.65 per share. This result was in line with the consensus of the 18 analysts following the company and under-performed last year's 2nd quarter results by 8.93%.
The next earnings announcement is expected on Oct 25, 2024.
Average growth rate-1.63%
AbbVie Inc reported annual 2023 earnings of 11.11 per share on Feb 02, 2024.
Average growth rate+6.81%
More ▼

Revenue history & estimates in USD

AbbVie Inc. had 2nd quarter 2024 revenues of 14.46bn. This bettered the 14.03bn consensus of the 19 analysts covering the company. This was 18.30% above the prior year's 2nd quarter results.
Average growth rate+1.67%
AbbVie Inc. had revenues for the full year 2023 of 54.32bn. This was 6.44% below the prior year's results.
Average growth rate+14.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.